• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The TARGET: Energy density of enteral nutrition not associated with mortality

byDayton McMillan
November 8, 2018
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients undergoing mechanical ventilation randomized to receive energy-dense enteral nutrition experienced similar rates of mortality at 90-days compared to patients treated with routine energy density enteral nutrition.

2. Patients receiving energy-dense nutrition experienced similar rates of complications or adverse events patients receiving routine enteral nutrition.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Critically ill patients often do not receive adequate caloric intake to match their energy expenditure. Previous studies differ in their assessment of whether “permissively underfeeding” patients is clinically harmful, and studies evaluating feeding patients with greater than standard caloric intake have often not been ideally designed. The randomized Augmented versus Routine Approach to Giving Energy Trial (TARGET) assessed how 90-day all-cause mortality rates differed in critically ill patients receiving either standard or energy-dense enteral nutrition. No difference in all-cause mortality was detected between the two treatment groups, and pre-specified secondary outcomes such as rates of adverse events, receipt of organ support, and number of days alive and out of the intensive care unit (ICU) did not differ between treatment groups.

This study provided a robust means of evaluating how nutritional support which differs by significant caloric values can affect mortality in critically ill patients. Strengths of the study include its randomized design, large number of patients included, and extensive subgroup analysis. Limitations include lack of measurement of patient energy expenditure and constrained inclusion of surgical or trauma patients.

Click to read the study, published today in NEJM

Relevant Reading: Parenteral vs. enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle

RELATED REPORTS

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

Medical cannabis provides little improvement to sleep in chronic pain patients

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

In-Depth [randomized controlled trial]: This multicenter, double-blind, randomized controlled trial was conducted between 2016 and 2017. Eligible adult patients were undergoing mechanical ventilation and had not yet begun enteral nutrition or had done so in the previous 12 hours. Patients were excluded if death was soon anticipated. Patients were randomized to receive either energy-dense (1.5 kcal/mL, n=1971) or routine (1.0 kcal/mL, n=1986) enteral nutrition and all patients received nutrition at a rate of 1 mL/hr. Enteral nutrition was continued up to 28 days, until the patient died, or until they were discharged from the ICU (whichever occurred first). The primary outcome was all-cause mortality at 90-days. Patients in the energy-dense group received on average 1863 kcal/day, while the routine group received on average 1262 kcal/day. At 90-days 26.5% of patients in the energy-dense group had died compared to 25.7%  of patients in the routine group (relative risk [RR], 1.05; 95% confidence interval [CI], 0.94 to 1.16). For secondary outcomes, no difference was detected between treatment groups for death by 28-days, percentage of patients with positive blood cultures, frequency of adverse events, or receipt of vasopressor or renal support. Prespecified subgroup analysis showed no difference between treatment groups for 90-day overall mortality when evaluating by patients with or without trauma, with or without sepsis, receiving medical or surgical treatment, or by body mass index (BMI) groupings.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Previous Post

Quick Take: Association of Weather With Day-to-Day Incidence of Myocardial Infarction: A SWEDEHEART Nationwide Observational Study

Next Post

Zoliflodacin (ETX0914) effectively treats urogenital gonorrhea

RelatedReports

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
StudyGraphics

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

May 27, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
USPSTF recommends routinely screening asymptomatic women for chlamydia and gonorrhea

Zoliflodacin (ETX0914) effectively treats urogenital gonorrhea

Inhaled inorganic nitrites do not improve exercise capacity in heart failure with preserved ejection fraction

Reperfusion therapy may be suboptimal for STEMIs requiring transfers

Sensitive cardiac injury marker could reduce stress testing for myocardial ischemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.